Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study
Liver Cancer · 18.12.2024 · 14 (4) · 391-407
DOI: 10.1159/000542285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 18.12.2024. Verfasst von Yoon Jun Kim und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul, Republic of Korea. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
In the phase 3 RESORCE trial, regorafenib prolonged overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC) whose disease progressed on prior sorafenib. The prospective, observational REFINE study aimed to evaluate the safety and effectiveness of regorafenib in a broader population of patients in real-world clinical practice, including patients with Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2, Child-Pugh B liver status, and sorafenib intolerance.
Methods
This international, prospective, multicenter study (NCT03289273) enrolled patients with uHCC for whom the decision to treat with regorafenib was made by their physician before enrollment, according to the local health authority-approved label. The primary aim was to evaluate the safety of regorafenib, including the incidence of treatment-emergent adverse events (TEAEs) and dose modifications due to TEAEs.
Results
Of the 1,028 patients enrolled, 1,005 initiated regorafenib and were eligible for analysis. Median age was 66 years (range 21–94); most patients were male (83%), Child-Pugh A (61%), and had an ECOG PS of 0 or 1 (82%) at study entry. Overall, 47%, 11%, and 40% of patients initiated regorafenib at 160, 120, and 80 mg/day, respectively. Median treatment duration was 3.7 months (range 1 day to 38.9 months). Dose modifications and permanent discontinuation of regorafenib due to TEAEs occurred in 45% and 31% of patients, respectively. The most common drug-related TEAEs were hand-foot skin reaction (31%), diarrhea (26%), and fatigue (15%). Median OS was 13.2 months (95% confidence interval 11.6, 14.8).
Conclusion
The results of the real-world REFINE study confirmed the safety and effectiveness of regorafenib in a broad population of patients with uHCC. Of patients who received standard regorafenib dosing in REFINE, safety and efficacy findings were consistent with those reported in the RESORCE trial.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
- Department of Hepatology and Gastroenterology, Groupement Hospitalier Lyon Nord, Hôpital de la Croix-Rousse, Lyon, France.
- Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
- Department of Medical Oncology, Faculty of Medicine, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
- Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Zitieren
APA
Kim, Y. J., Merle, P., Finn, R. S., Kudo, M., Klümpen, H. J., Lim, H. Y., Ikeda, M., Granito, A., Masi, G., Gerolami, R., Cho, S. B., Hsu, C. H., Huang, Y. H., Jeng, L. B., Kim, D. Y., Lin, S. M., Pinter, M., Shao, G., Kato, N., …, & Qin, S. (2024). Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study. Liver Cancer, 14(4), 391-407. https://doi.org/10.1159/000542285
Vancouver
Kim YJ, Merle P, Finn RS, Kudo M, Klümpen HJ, Lim HY, et al. Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study. Liver Cancer. 2024;14(4):391-407. doi:10.1159/000542285
BibTeX
@article{Kim2024,
author = {Kim, Yoon Jun and Merle, Philippe and Finn, Richard S and Kudo, Masatoshi and Klümpen, Heinz-Josef and Lim, Ho Yeong and Ikeda, Masafumi and Granito, Alessandro and Masi, Gianluca and Gerolami, René and Cho, Sung Bum and Hsu, Chih-Hung and Huang, Yi-Hsiang and Jeng, Long-Bin and Kim, Do Young and Lin, Shi-Ming and Pinter, Matthias and Shao, Guoliang and Kato, Naoya and Kurosaki, Masayuki and Numata, Kazushi and Kuo, Kung-Kai and Mao, Yilei and Lin, Yih-Jyh and Zhu, Kangshun and Twumasi-Ankrah, Philip and Khan, Javeed and Awan, Maria and Ozgurdal, Kirhan and Qin, Shukui},
title = {Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study},
journal = {Liver Cancer},
year = {2024},
volume = {14},
number = {4},
pages = {391--407},
doi = {10.1159/000542285}
}
EUVIMED